Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ

$36.24

+$0.01 (0.03%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$35.82$36.81

Open $36.68

52 Week Range

$25.81$46.75

Previous Close $36.23

Market Cap3.49B

Volume1.41M

Avg Volume1.50M

P/E (TTM)-6.24

EPS (TTM)$-5.81

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Ultragenyx Pharmaceutical Inc.

DEC112025

CENTURY LITHIUM HIGHLIGHTS RARE EARTH POTENTIAL AT ANGEL ISLAND, NEVADA

Source: PRNewsWire•5 days ago

VANCOUVER, BC , Dec. 11, 2025 /PRNewswire/ - Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) ("Century Lithium" or "the Company") is pleased to provide further details regarding its recent news release on the recovery of rare earth ...

DEC22025

CENTURY LITHIUM ACHIEVES HIGH RECOVERY OF RARE EARTH AND CRITICAL ELEMENTS FROM PRIMARY LEACH SOLUTIONS

Source: PRNewsWire•14 days ago

VANCOUVER, BC , Dec. 2, 2025 /PRNewswire/ - Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) ("Century Lithium" or "the Company") is pleased to report positive results from its ongoing test work on the recovery of rare earth elements...

NOV42025

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Source: GlobeNewsWire•41 days ago

Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price Proceeds to fund four expec...

OCT302025

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Source: PRNewsWire•47 days ago

ENCINITAS, Calif. and WASHINGTON D.C....

OCT282025

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Source: GlobeNewsWire•48 days ago

NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today an...

OCT242025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Source: GlobeNewsWire•52 days ago

NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the gran...

OCT32025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Source: GlobeNewsWire•73 days ago

NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the gran...

SEP302025

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Source: GlobeNewsWire•76 days ago

NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the pl...

SEP192025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Source: GlobeNewsWire•87 days ago

NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the gra...